These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11139136)

  • 1. Applications of pharmacogenetics to drug development: the Glaxo Wellcome experience.
    Arledge T; Freeman A; Arbuckle J; Mosteller M; Manasco P
    Drug Metab Rev; 2000; 32(3-4):387-94. PubMed ID: 11139136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global gene mining and the pharmaceutical industry.
    Knudsen LE
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):679-83. PubMed ID: 15979678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Family consent and the pursuit of better medicines through genetic research.
    Renegar G; Rieser P; Manasco P
    J Contin Educ Health Prof; 2001; 21(4):265-70. PubMed ID: 11803771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global requirements for DNA sample collections: results of a survey of 204 ethics committees in 40 countries.
    Ricci DS; Broderick ED; Tchelet A; Hong F; Mayevsky S; Mohr DM; Schaffer ME; Warner AW; Hakkulinen P; Snapir A
    Clin Pharmacol Ther; 2011 Apr; 89(4):554-61. PubMed ID: 21346753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-based pharmacogenetics and the pharmaceutical industry.
    Roses AD
    Nat Rev Drug Discov; 2002 Jul; 1(7):541-9. PubMed ID: 12120260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exception from informed consent: viewpoint of institutional review boards--balancing risks to subjects, community consultation, and future directions.
    Ernst AA; Fish S
    Acad Emerg Med; 2005 Nov; 12(11):1050-5. PubMed ID: 16264073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of clinical trials by Ethics Committees in Germany--results and a comparison of two surveys performed among members of the German Association of Research-Based Pharmaceutical Companies (vfa).
    Russ H; Busta S; Jost B; Bethke TD
    Ger Med Sci; 2015; 13():Doc02. PubMed ID: 25698912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance.
    Brazell C; Freeman A; Mosteller M
    Br J Clin Pharmacol; 2002 Mar; 53(3):224-31. PubMed ID: 11874384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics: the Rx perspective.
    Renegar G; Rieser P; Manasco P
    Expert Rev Mol Diagn; 2001 Sep; 1(3):255-63. PubMed ID: 11901830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics and disease genetics of complex diseases.
    Schmith VD; Campbell DA; Sehgal S; Anderson WH; Burns DK; Middleton LT; Roses AD
    Cell Mol Life Sci; 2003 Aug; 60(8):1636-46. PubMed ID: 14504654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of institutional review board practice variation on observational health services research.
    Green LA; Lowery JC; Kowalski CP; Wyszewianski L
    Health Serv Res; 2006 Feb; 41(1):214-30. PubMed ID: 16430608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics: role in medicines approval and clinical use.
    Novelli G; Borgiani P; Ciccacci C; Di Daniele N; Sirugo G; Papaluca Amati M
    Public Health Genomics; 2010; 13(5):284-91. PubMed ID: 19815999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision Medicine and the Institutional Review Board: Ethics and the Genome.
    Matrana MR; Campbell B
    Ochsner J; 2020; 20(1):98-103. PubMed ID: 32284690
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Society and ethics - the genetics of disease.
    Thomas SM
    Curr Opin Genet Dev; 2004 Jun; 14(3):287-91. PubMed ID: 15172672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coding of DNA samples and data in the pharmaceutical industry: current practices and future directions--perspective of the I-PWG.
    Franc MA; Cohen N; Warner AW; Shaw PM; Groenen P; Snapir A;
    Clin Pharmacol Ther; 2011 Apr; 89(4):537-45. PubMed ID: 21346752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Problematic variation in local institutional review of a multicenter genetic epidemiology study.
    McWilliams R; Hoover-Fong J; Hamosh A; Beck S; Beaty T; Cutting G
    JAMA; 2003 Jul; 290(3):360-6. PubMed ID: 12865377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.